GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine

HIV Clinical Trials

Volumn 2, Issue 4, 2001, Pages 307-316

  Arasteh, K ^a   Wood, R ^a   Muller M ^a   Prince, W ^a   Cass, L ^a   Moore, K H P ^a   Dallow, N ^a   Jones, A ^a   Klein, A ^a   Burt, V ^a   Kleim, J P ^a  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

GW420867X; HIV 1; Nonnucleoside reverse transcriptase inhibitor

Indexed keywords

2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; CD4 ANTIGEN; HUMAN SERUM ALBUMIN; LAMIVUDINE; OROSOMUCOID; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLOGIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SLEEP DISORDER;

EID: 0034893889     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/03CY-NCM5-8DQG-L2KY     Document Type: Article

References (22)

1. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication
2. Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study
3. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors
4. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) - Initial phase evaluation
5. Effect of high fat and normal meals on the relative bioavailabillity of GW420867X 100 mg administered as a single oral dose to healthy volunteers
6. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
7. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
8. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1
9. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
10. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptase by the phenyl ethyl thiozolyl thiourea derivatives trovirdine and MSG-127
11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
12. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection
13. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells per cubic millimetre (ACTG 261)
14. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection
15. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients
16. High dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication
17. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease
18. GW420867X, a new non-nucleoside reverse transcriptase inhibitor (NNRTI), repeat dose pharmacokinetics and single rising dose pharmacokinetics (PK)
19. GW420867X: A novel quinoxaline-class NNRTI of HIV-1 with improved antiviral properties in the presence of human serum and its components
20. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection
21. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
22. A dose ranging study to evaluate the efficacy and safety of MKC-442 in HIV-infected patients